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The  physiological  process  by which  Ca2+ is released  from  the  sarcoplasmic  reticulum  is called  excitation-
contraction  coupling;  it  is  initiated  by an  action  potential  which  travels  deep  into  the  muscle  fiber  where
it  is  sensed  by  the  dihydropyridine  receptor,  a voltage  sensing  L-type  Ca2+channel  localized  on the
transverse  tubules.  Voltage-induced  conformational  changes  in the  dihydropyridine  receptor  activate
the ryanodine  receptor  Ca2+ release  channel  of  the sarcoplasmic  reticulum.  The released  Ca2+ binds  to
troponin  C, enabling  contractile  thick-thin  filament  interactions.  The  Ca2+ is  subsequently  transported
back  into  the sarcoplasmic  reticulum  by  specialized  Ca2+ pumps  (SERCA),  preparing  the muscle  for  a
new cycle  of contraction.  Although  other  proteins  are  involved  in excitation-contraction  coupling,  the
mechanism  described  above  emphasizes  the  unique  role played  by  the  two  Ca2+ channels  (the  dihy-
dropyridine  receptor  and  the  ryanodine  receptor),  the  SERCA  Ca2+ pumps  and  the  exquisite  spatial
organization  of the membrane  compartments  endowed  with  the  proteins  responsible  for  this  mech-
anism  to function  rapidly  and  efficiently.  Research  over  the  past  two  decades  has  uncovered  the  fine
details  of excitation-contraction  coupling  under  normal  conditions  while  advances  in genomics  have
helped  to identify  mutations  in  novel  genes  in  patients  with  neuromuscular  disorders.  While  it is now
clear  that  many  patients  with  congenital  muscle  diseases  carry mutations  in  genes  encoding  proteins
directly  involved  in  Ca2+ homeostasis,  it has  become  apparent  that mutations  are  also  present  in  genes
encoding  for proteins  not  thought  to be directly  involved  in  Ca2+ regulation.  Ongoing  research  in the  field
now  focuses  on  understanding  the  functional  effect  of  individual  mutations,  as  well  as  understanding  the
role of proteins  not  specifically  located  in  the  sarcoplasmic  reticulum  which  nevertheless  are  involved  in
Ca2+ regulation  or excitation-contraction  coupling.  The  principal  challenge  for  the future  is  the  identifi-
cation  of drug  targets  that  can be pharmacologically  manipulated  by  small  molecules,  with  the  ultimate
aim  to improve  muscle  function  and  quality  of life  of patients  with congenital  muscle  disorders.  The  aim
of  this  review  is to  give  an  overview  of the most  recent  findings  concerning  Ca2+ dysregulation  and  its
impact  on  muscle  function  in  patients  with  congenital  muscle  disorders  due to  mutations  in  proteins
involved  in  excitation-contraction  coupling  and  more  broadly  on  Ca2+ homeostasis.
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perspectives, Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.s
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. Introduction
.1. The sarcoplasmic reticulum and Ca2+ regulation
The sarcoplasmic reticulum (SR) is a specialized intracellular
embrane compartment present in striated muscles and almost
ompletely dedicated to Ca2+ regulation. The SR can be subdivided
nto different functional domains that are each enriched in specific
a2+ handling and structural proteins. The transverse tubules (T-
ubules) are invaginations of the plasma membrane and contain
he voltage sensing dihydropyridine receptor (DHPR). The portion
f the SR terminal cisternae membrane facing the T-tubules is
alled junctional face membrane and contains the ryanodine recep-
or Ca2+ release channel (RyR1), regulatory and structural proteins
uch as JP-45, triadin and junctin as well as a number of other
roteins that are part of the RyR1 Ca2+ release channel macromolec-
lar structure [1–4]. In skeletal muscle, the triad, i.e. the structure
ormed by the T-tubule and two sarcoplasmic reticulum terminal
isternae is the membrane domain directly involved in excitation-
ontraction coupling. Fig. 1 illustrates the main protein components
f the excitation-contraction coupling machinery in mammalian
keletal muscle.
The sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA)
s the main protein of the longitudinal sarcoplasmic reticulum,
ccounting for >70% of its total protein content. SERCAs belong to
lass P-type ATPases and are responsible for replenishing the SR
ith Ca2+ after its release following excitation- contraction cou-
ling [2,4,5]. In striated muscle, SERCA activity can be modulated
y two small regulatory proteins, sarcolipin and phospholamaban
5,6]. Sarcolipin decreases the affinity of SERCA1a for Ca2+ thereby
nhibiting its re-uptake in the SR at submciromolar Ca2+. In humans
t is expressed in both fast and slow twitch muscles as well as in
ardiac muscle [7,8]. Phospholamban, which is expressed in car-
iac and slow twitch muscles, acts as an inhibitor of SERCA2a when
resent in the unphosphorylated form, but upon phosphorylation
y PKA its inhibitory effects are abolished [9,10]. Interestingly sar-
olipin and phospholamban share ∼30% identity and have been
roposed to bind to the same domain on SERCA2a [5,6,11]. Myoreg-
lin is a recently identified skeletal muscle-specific micropeptide
haring structural similarities with sarcolipin and phospholamban.
yoregulin interacts with SERCA1 and by so doing decreases the
1.2. Excitation-contraction coupling
Excitation-contraction coupling (ECC) is the process whereby
an electrical signal generated by an action potential is converted
into a chemical gradient, that is, an increase in the myoplasmic
[Ca2+], leading to muscle contraction [13,14]. Efficient ECC relies
on a highly sophisticated subcellular architecture, where voltage
sensing L-type Ca2+ channels (DHPRs) lie opposite RyR1 in a highly
organized conformation resembling a checkerboard, with every
other RyR1 tetramer facing four DHPRs arranged in a characteristic
square shape called a tetrad [15,16]. The DHPR is a macromolecu-
lar complex made up of at least five subunits present in a 1:1:1:1:1
ratio, including Cav1.1 (or 1.1), the channel pore that interacts
through its II–III loop with the RyR1, as well as the 2, ß, 
and ∂ subunits [17]. Several diseases have been linked to muta-
tions in CACNA1S, the gene encoding Cav1.1, including some forms
of hypokalemic periodic paralysis and malignant hyperthermia
[18–20].
The RyR1 is a huge macromolecular complex of >2.5 MDa  made
up of 4 homotetramers of ≈565 kDa each that assemble into a func-
tional Ca2+ release channel. The first 4000 amino acids make up the
large cytoplasmic domain that contains binding sites for various
modulators, while the last 1000 amino acids constitute the carboxy
terminal pore-forming domain [21,22]. Dominant and recessive
mutations in RYR1, the gene encoding the RyR1, are associated
with a range of early-onset neuromuscular disorders including the
core myopathies central core disease (CCD) and multi-minicore
disease (MmD), congenital fiber type disproportion, (CFTD) cen-
tronuclear myopathy (CNM), exertional rhabdomyolysis/myalgia
as well as the pharmacogenetic disorder malignant hyperthermia
(MH) [23–26].
Aside the RyR1, the junctional sarcoplasmic reticulum is
enriched in several other proteins including the structural pro-
teins triadin and junctin, as well as minor constituents such as
JP-45, junctate and humbug, mitsugumin-29, SRP-27/TRIC-A and
junctophilin-1 [4,27–29]. These minor constituents play a role in
the fine regulation of Ca2+ release from the SR or are involved in
maintaining the structural integrity of the Ca2+ release machinery.
Another major constituent of the junctional SR is the high capacity,
low affinity Ca2+ binding protein calsequestrin. In the presence of
millimolar Ca2+ (that is, at a concentration similar to that present atPlease cite this article in press as: S. Treves, et al., Ca2+ handling ab
perspectives, Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.s
ump’s activity [12]. Its deletion in mice enhances Ca2+ handling
nd improves exercise performance, suggesting that myoregulin
lays an important physiological role in regulating skeletal muscle
a2+ homeostasis.normalities in early-onset muscle diseases: Novel concepts and
emcdb.2016.07.017
rest in the lumen of the SR), calsequestrin polymerizes and forms
a mesh-like structure in an area adjacent to the RyR1 where it acts
as the principal SR Ca(2+) storage protein. [29–31]. The luminal
domain of junctin interacts directly with calsequestrin and together
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Fig. 1. Schematic representation of the protein components of skeletal muscle sar-
coplasmic reticulum (reproduced from [4]). The DHPRs (2) in the transverse tubules
face the RyR1 s (1) on the terminal cisternae junctional face membrane. The struc-
tural proteins triadin (TRISC, 5) and junctin (6) are shown to interact with the
carboxy-terminal domain of the RyR1 and with the luminal calcium binding protein
calsequestrin (CSQ, 3). The luminal domain of JP-45 (7) interacts with calsequestrin
while its cytoplasmic domain interacts with the DHPR. The SERCA pumps (4) are
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bn  the longitudinal sarcoplasmic reticulum; the minor protein components junc-
ate  (8), mitsugumin- 29 (MG-29, 9) and junctophillin (11) are also indicated. Red
pheres represent Ca2+ ions; yellow spheres represent K+ ions.
ith triadin forms a complex that is thought to have a dual role:
i) maintaining calsequestin adjacent to the RyR1 and (ii) sensing
he amount of Ca2+ in the lumen of the SR [31,32]. Two  isoforms of
alsequestrin have been identified: calsequestrin1 that is predom-
nantly expressed in fast twitch skeletal muscles and calsequestrin
 that is expressed in cardiac and slow twitch muscle. Mutations in
SQ2 (the gene encoding calsequestrin 2) have been linked to cate-
holaminergic polymorphic ventricular tachycardia (CPVT), sudden
ardiac arrest and heart failure [33,34] and will not be discussed
n this review, whereas mutations in CSQ1 (the gene encoding
alsequestrin 1) have been implicated in rare cases of malignant
yperthermia and vacuolar aggregate myopathy [35,36].
. Pathological consequences of mutations in genes
ncoding proteins directly involved in ECC
.1. Disorders associated with RYR1 mutations
The first mutation identified in RYR1, the gene encoding the
keletal muscle RyR1, was linked to Malignant Hyperthermia
usceptibility (MHS), a pharmacogenetic disorder triggered by
alogenated anesthetics and by the muscle relaxant succinyl-
holine [37]. Since this initial discovery in the early 90s, more
han 200 mutations have been identified in patients with a variety
f inherited myopathies including MHS, exertional rhabdomyoly-
is/myalgia and a range of congenital myopathies including CCD,
s well as subgroups of MmD,  CNM and CFTD [23–26]. Because of
he sheer size of the RYR1 gene which spans 106 exons and >15 kb
NA, initial mutation searches were confined to hotspot domains
riginally implicated in autosomal dominant MHS  and CCD. How-
ver, thanks to technical advances in DNA sequencing and genome
nalysis, a more systematic examination of the RYR1 gene became
ossible and revealed that mutations, especially recessive ones, can
ffect the entire coding region of the RYR1 gene. The calculated fre-
uency of RYR1 mutations is approximately 1:3000 making it one ofPlease cite this article in press as: S. Treves, et al., Ca2+ handling ab
perspectives, Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.s
he most commonly mutated genes associated with neuromuscular
isorders [38–40]. A number of reviews concerning the frequency,
isease associations and functional impact of RYR1 mutations have
een published in recent years and the reader is referred to these for PRESS
mental Biology xxx (2016) xxx–xxx 3
a more in depth description (for example see [12–24,41–45]). The
disease phenotype resulting from RYR1 mutations largely depends
on their location within the RYR1 coding sequence and whether
the mutations are dominant or recessive. Dominant mutations are
more commonly associated with the MHS  or exertional rhabdomy-
olysis and CCD phenotypes, while most cases of MmD,  CNM and
CFTD are associated with recessive mutations. From a general point
of view, dominant RYR1 mutations affect the biophysical properties
of the Ca2+ channel while the mode of action of recessive mutations
has been more difficult to decipher.
For gain-of-function dominant MHS-linked mutations that ren-
der the Ca2+ channel hypersensitive and thus more prone to be in
the open conformation, the amino acid substitutions induce local
protein misfolding or affect the intersubunit domain–domain inter-
faces; the resulting tetrameric channels are deregulated leading to
a leak of Ca2+ into the cytoplasm or to an excessive amount of Ca2+
release from the SR [22,24,46–49]. This results in a number of direct
effects in the muscle fibers including a higher resting cytosolic
[Ca2+], a shift in the sensitivity to activating signals (depolarization,
pharmacological stimulation) or greater depolarization-induced
Ca2+ influx, all of which can lead to a hypermetabolic state which
is the underlying feature of MHS.
Dominant mutations associated with CCD induce weak mus-
cles either because they render the RyR1 channels less efficient at
transporting Ca2+, or because they lead to intraluminal SR Ca2+ store
depletion [50,51]. Although understanding precisely the functional
impact of the mutation is important in order to develop an appro-
priate pharmacological approach, both types of mutations lead to
changes in the biophysical properties of the RyR1 and cause weak
muscles because Ca2+ is not available to bind to the contractile
proteins and initiate contraction.
Two  important aspects concerning the effects of dominant RYR1
mutations still require clarification. One relates to the protomer
composition of the Ca2+ channel in individuals carrying dominant
RYR1 mutations, while the other is related to secondary down-
stream effects. It is very difficult, if not impossible, to establish
the exact protomer composition of the RyR1 protein complex in
individuals carrying dominant RYR1 mutations. A variation in the
proportion of protomers encoded by wild type and mutated alleles
within the tetrameric RyR1 Ca2+ channel complex will undoubtedly
affect the biophysical properties of the Ca2+ channel [52], possibly
contributing to the phenotypic variation seen in patients carrying
the same RYR1 mutations. The primary defects in Ca2+ regulation
caused by dominant RYR1 mutations will also lead to secondary
downstream effects in the muscle fibers, such as increased release
of inflammatory cytokines, mitochondrial abnormalities, modifi-
cations due to the excessive generation of reactive oxygen and
nitrogen species, and changes in transcriptional regulation, includ-
ing those that are dependent on activation of the Ca2+–sensitive
NFAT transcription factors [50,53,54]. An example of such an effect
is illustrated in Fig. 2, showing that in myotubes from patients with
CCD carrying dominant RYR1 mutations, the nuclear to cytoplasmic
ratio of NFATc1 is higher than in myotubes from control individuals,
under resting non-stimulated conditions. Furthermore, the nuclear
to cytoplasmic ratio of NFATc1 increases dramatically after KCl-
induced depolarization (Fig. 2A and B) [53]. Moreover, even in the
absence of inflammatory conditions (as suggested by the lack of
upregulation of the C-reactive protein, a marker of inflammation)
the serum content of pro-inflammatory cytokines such as IL-6 is
chronically elevated in individuals carrying dominant RYR1 muta-
tions (panel C), but the functional consequences of such changes
are largely unknown.normalities in early-onset muscle diseases: Novel concepts and
emcdb.2016.07.017
From Fig. 2 it is also apparent that the control and MmD
(expressing recessive RYR1 mutations) groups are more similar in
their serum IL-6 levels and this is probably linked to the functional
effect of the mutations. Indeed, in myotubes from patients with
Please cite this article in press as: S. Treves, et al., Ca2+ handling abnormalities in early-onset muscle diseases: Novel concepts and
perspectives, Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.semcdb.2016.07.017
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Fig. 2. Prolonged depolarization induces nuclear translocation of NFAT and may  be linked to increased level of circulating IL-6. A. Myotubes from a control and CCD individual
were  untreated or treated with 500 M ryanodine and incubated with 60 mM KCl for 20 s and then with Krebs Ringer for a total of 5 min at 37 ◦C. Cells were fixed and processed
for  immunofluorescence. Images (60X TIRF objective) show epifluorescence using anti-NFATc1 Ab (green) and DAPI (blue) for nuclear staining. Bar = 30 m. B. Bar histograms
showing the nuclear to cytoplasmic NFATc1 fluorescence intensity in cells from 3 different control individuals (n ranged between 25 and 35 individual cells) and 2 different
CCD  individuals (n ranged between 32 and 38 individual cells) in untreated cells (white bars) and cells treated with 60 mM KCl plus 2 mM Ca2+ for 20 s and then incubated
with  Krebs Ringer for 5 min  (light grey) or 30 min (dark grey). The area over the nucleus was  selected using the DAPI image and transferred to the NFATc1 fluorescence image
using  the “transfer region option” of the Metamorph software package. Average fluorescent intensity in nuclei and region excluding nuclei were calculated with Metamorph.
*P  < 0.03 compared to controls (from [53]). C. Plot of (logarithmic) serum concentrations of IL-6 in different groups of patients. Each symbol represents the mean triplicate
IL-6  value obtained from a single individual. P values were statistically significant between controls and MHS  individuals and control and CCD patients.
Fig. 3. Cartoon depicting how mutations in RYR1 may  lead to a decrease in RyR1 content. Recessive mutations in the RYR1 gene are accompanied by epigenetic modifications
leading  to DNA hyper-methylation and HDAC-4/HDAC-5 over-expression. This causes mef-2 sequestration thereby inhibiting transcription of genes regulated by mef-2,
including the RYR1 and muscle-specific miRs. A decrease in RyR1 would severely affect muscle excitation-contraction coupling since this calcium channel is a central player
in  this mechanism, releasing the calcium necessary for muscle contraction from the sarcoplasmic reticulum.
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ecessive RYR1 mutations no dysregulation of Ca2+ homeostasis
as detected [55]. This result is puzzling since muscle biopsies
rom the same patients show significant depletion of RyR1 pro-
ein, which should lead to a pronounced reduction of the amount
f Ca2+ released following RyR1 activation [55–57]. In a recent
tudy we addressed the pathophysiology of recessive RYR1 muta-
ions and in particular the epigenetic mechanism(s) responsible
or bringing about such a drastic decrease of RyR1 protein in the
uscles of patients [55]. Interestingly, most patients harboring
ecessive RYR1 mutations exhibit a 6–16 fold increase in class II
istone de-acetylase protein content (HDAC-4 and HDAC-5) and
ypermethylation of (at least) a CpG island within the RYR1 gene.
lass II HDACs can bind to and sequester the muscle transcrip-
ion factor mef-2 [58], thus one would expect that an increase
n HDAC-4/5 expression would prevent the transcription of mef-
 dependent genes. The transcription of miR-1 and miR-133 has
een shown to be mef-2 dependent [59] and the 5′ region of the
YR1 contains a mef-2 binding domain [60]. Furthermore, since
iR-22 and miR-124 have binding sites within the 3′UTR of the
YR1 their transcription may  be linked to that of their binding
artner RYR1. These results are compatible with and explain our
ndings in muscle biopsies of patients with recessive RYR1 muta-
ions who not only showed reduced RyR1 protein levels, but also
educed myomesin content (a mef-2 dependent protein) and a sig-
ificant down-regulation of muscle specific micro RNAs including
iR-22, miR-124, miR-1 and miR-133 [55]. Our working hypothesis
s illustrated in Fig. 3 where it is shown that the down-regulation
f RyR1 is a consequence of the activation of a pathological epi-
enetic loop in skeletal muscle. These results are novel and will
equire further investigations in animal models, but if confirmed
hey will open new pathways for the treatment of muscle disorders
hich would then not target directly the primary genetic defect,
ut the downstream effects (in this case methylation and HDAC
ctivation) which are hyperactivated in patients with neuromus-
ular diseases due to recessive RYR1 mutations and possibly also in
atients with neuromuscular disorders due to mutations in other
enes, increasing the significance of these findings.
.2. Disorders associated with CACNA1S mutations
In skeletal muscle, the RyR1 and DHPR constitute a signaling
omplex whereby orthograde (or forward) coupling between the
wo complexes activates Ca2+ release from luminal SR stores via
he opening of RyR1 channels, while retrograde signaling from
he RyR1 back to the DHPR regulates the magnitude of the L-type
nward Ca2+ current from the extracellular space into muscle cells
arried by the DHPR [13,14,21]. In primary myotubes, depolarizing
timuli that do not substantially deplete SR Ca2+ stores can rapidly
ctivate extracellular Ca2+ entry by a mechanism called excitation
oupled Ca2+ entry (ECCE) that occurs through a complex made
p of RyR1 and DHPR, the latter having dual functions not only
s the voltage sensor for EC coupling but also as an L-type Ca2+
hannel [61,62]. Experimental evidence supporting a pathogenic
ole of enhanced ECCE in MHS  was provided by Cherednichenko
t al. [63] in mice knocked in for the RYR1 p.R163C mutation. Stud-
es on skeletal muscles from these mice demonstrated: (i) that they
xhibited enhanced depolarization-induced Ca2+ entry, (ii) that this
nflux of Ca2+ did not occur via store activated Ca2+ entry, but via
CCE and (iii) that it is sensitive to dantrolene, the drug that is
linically used to revert MH  reactions. Increased ECCE in myotubes
rom patients with dominant RYR1 mutations was  also observedPlease cite this article in press as: S. Treves, et al., Ca2+ handling ab
perspectives, Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.s
y Treves et al. [53] providing further experimental evidence that
athological dysregulation of Ca2+ homeostasis is not only caused
y effects on the RyR1 Ca2+ release, but also by alteration of extra-
ellular Ca2+ influx into skeletal muscles. PRESS
mental Biology xxx (2016) xxx–xxx 5
Although more than 50% of MHS  cases are caused by RYR1 muta-
tions that render the Ca2+ channel hypersensitive, rare mutations
either at the heterozygous or homozygous state have been identi-
fied in CACNA1S, the gene encoding the 1.1 subunit of the DHPR
[18–20,64]. The presence of the CACNA1S p.R174W mutation affects
Ca2+ homeostasis by altering the regulation of the RyR1 by Cav1.1.
The RyR1 becomes leaky, resulting in an increased resting cytosolic
[Ca2+] and partial depletion of SR Ca2+ stores. Though no studies on
Ca2+ influx or altered ECCE were performed on cells carrying this
mutation, the increased resting [Ca2+] was insensitive to nifedipine
suggesting that, at least in this case, the pathological effect is due
to the lack of inhibition of RyR1-mediated Ca(2+) leak by the DHPR
at rest [65]. Similar conclusions were reached when studying the
effects of the CACNA1S p.R1086H mutation in myotubes, although in
the latter case the CACNA1S mutation results in the enhanced sensi-
tivity of the RyR1 to activation by both endogenous and exogenous
activators [66].
2.3. STAC3 mutations and Native American myopathy
The first indication that patients with Native American myopa-
thy, a peculiar myopathy affecting the Native American Lumbee
population, may  have a defect in Ca2+ regulation was the finding
that they have an increased susceptibility to Malignant Hyperther-
mia, in the absence of RYR1 mutations [67]. Many individuals with
Native American myopathy however, present a phenotype that
is reminiscent of that of patients with RYR1 mutations, including
progressive scoliosis, short stature and dysmorphic features resem-
bling RYR1-related King Denborough syndrome KDS [67,68]. The
first report regarding the underlying molecular mechanism of this
disorder was  the identification of the recessive STAC3 p.W284 S
mutation in patients with Native American myopathy. Subse-
quently genetic characterization of a spontaneous zebrafish mutant
showing defective swimming revealed that it carried a point muta-
tion in the fish homologue of STAC3.  The mutation disrupted a splice
donor site, leading to the inclusion of intron 4 and a premature stop
codon and to the absence of the stac3 protein from skeletal muscle
[[69] and Muntoni et al., personal observation]. The ECC mecha-
nism of these mutant fish was severely compromised as shown by
the reduced Ca2+ transients in both fast and slow twitch muscles,
but there were no changes in the architecture of the T-tubules or
SR membranes, even though Stac3 forms a complex with the DHPR
and RyR1.
Stac3 KO mice die soon after birth because of breathing impair-
ment [70,71]; muscles from newborn mice exhibit a decrease in
muscle mass, centrally located nuclei and importantly, no contrac-
tion and no Ca2+ release in response to depolarization. Skeletal
muscles from Stac3 KO mice respond normally to the RyR1 pharma-
cological agonist 4-chloro-m-cresol, indicating that RyR1 function
is normal [71]. These results indicate that the absence of Stac3
affects the voltage sensing and L-type Ca2+ channel DHPR but not
the SR Ca2+ channels, a result that was confirmed recently when
it was  shown that in skeletal muscle Stac3 is required for surface
expression of Cav1.1 [72]. Clearly much remains to be investigated
on how defects in STAC3 cause such a strong muscle phenotype and
are linked to MHS.
2.4. CASQ1 mutations and vacuolar aggregate myopathy
Calsequestrin 1, the Ca2+ storing protein of skeletal muscle, is
a low affinity high capacity Ca2+ binding protein present in the
lumen of the SR. At luminal resting [Ca2+] calsequestrin forms poly-normalities in early-onset muscle diseases: Novel concepts and
emcdb.2016.07.017
mers that are thought to make available large amounts of Ca2+ in
close proximity to the RyR1. In the past two years, two reports
have appeared linking one mutation in CASQ1 to vacuolar aggre-
gate myopathy [35,73]. Patients carrying the heterozygous CASQ1
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.D244G mutation, affecting a residue that lies within the Ca2+
inding domain of calsequestrin 1, have a mild myopathy, suffer
rom muscle cramps, elevated CK levels, reduced muscle strength
nd fatigue. From a functional point of view, muscle fibers iso-
ated from these patients show (i) decreased Ca2+ release following
affeine administration, (ii) increased glycogen content and mis-
riented SR junctions, (iii) an increase by approximately 25% of
alsequestrin 1 content and (iv) a lower content of polymerized
alsequestin [35,73]. Interestingly a report on the physicochemi-
al properties of wild type and p.D244G mutated CASQ1 showed
hat the mutation reduces the Ca2+ binding properties of calse-
uestrin 1 and causes it to form large aggregates in vitro [36]. It
hould be pointed out that all the patients identified so far were het-
rozygous for the causative CASQ1 mutation, while the functional
tudies were performed on homozygous mutated calsequestrin 1
olecules. Thus it is likely that the mild phenotype of the patients
ay be due to the presence of wild type calsequestrin 1 molecules
ithin the SR. Of interest, CASQ1 KO mice exhibit heat intolerance
eading to an MH-like phenotype, enhanced oxidative stress, mito-
hondrial damage and reduced levels of releasable Ca2+ [74,75].
. Congenital myopathies due to mutations in genes
nvolved in Ca2+ entry pathways and SR Ca2+ uptake
Skeletal muscle fibers express two distinct mechanisms of extra-
ellular calcium entry: (i) calcium entry activated by depletion
f sarcoplasmic reticulum stores (Store Operated Calcium Entry,
OCE) [76–78] and (ii) Ca2+ entry via the voltage sensing DHPR
1.1 subunit, also referred to as ECCE (see Section 2.2 where dis-
rders associated with CACNA1S mutations are described), which
s triggered either by a train of action potentials or by prolonged
epolarization [61,62,79].
.1. Disorders of SOCE: tubular aggregate myopathy
Dominant mutations in STIM1 and ORAI1 have been linked to
uscle disorders classified as tubular aggregate myopathy. This
roup of myopathies comprises rare, slowly progressive disorders
ausing either weakness or stiffness of proximal muscles [80–84].
TIM1 and ORAI1 encode respectively stromal interacting protein
(Stim1) and Orai1 or Calcium Release Activated Ca2+ Influx chan-
el (CRAC), proteins that are ubiquitously expressed and play a
ajor role in SOCE [85]. Remarkably, recessive loss-of-function
utations are associated with immune deficiency syndromes char-
cterized by T-cell dysfunction [80,81]. Two different models have
een proposed for the activation of SOCE, one is slow and occurs in
ost cells, while the other is rapid and occurs in skeletal muscle. In
esting conditions, Stim1 binds Ca2+ and is distributed throughout
he ER membrane, while Orai1 channels are localized on the plasma
embrane. Upon Ca2+ store depletion, Ca2+ unbinds from Stim1
ausing its re-localization to ER punctae adjacent to the plasma
embrane. The latter event leads to the recruitment of Orai1 into
he plasma membrane domain associated with ER punctae, and the
onformational coupling of Stim1 to Orai1 results in the activation
f SOCE. This process is slow, requiring tens of seconds to develop
n non-muscle cells [85]. In patients with loss of function muta-
ions in STIM1 and ORAI1 Ca2+ influx in T cells is severely affected,
esulting in impaired T-cell proliferation [80,81,86].
Evidence that depletion of Ca2+ from the SR activates Ca2+ entry
n skeletal muscles was unambiguously provided by Kurebayashi
nd Ogawa [76], who demonstrated that store depletion activatedPlease cite this article in press as: S. Treves, et al., Ca2+ handling ab
perspectives, Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.s
a2+ influx is sensitive to Ni2+ and resistant to nifedipine and that
t is inhibited by membrane depolarization. These results suggest
hat the properties of this Ca2+ influx pathway are similar to CRAC
hannels and some transient receptor potential canonical (TRPC) PRESS
mental Biology xxx (2016) xxx–xxx
channels. TRP channels are a family of relatively non-selective
cation channels predominantly expressed on the plasma mem-
brane that are often part of signaling complexes. There are 7 TRP
subfamilies encoded by 28–30 genes; members of the TRPC sub-
group play a role in Ca2+ influx. Using an elegant experimental
approach Launikonis and Rios [87] provided experimental results
supporting a role for SOCE in mammalian skeletal muscles. They
showed that in isolated rat EDL, SOCE: (i) is activated by release
of Ca2+ from the SR but does not require complete depletion of
Ca2+ stores; (ii) its rate of activation is independent of the magni-
tude of the Ca2+ transient; and (iii) occurs rapidly, requiring less
than 1 s following Ca2+ release from the SR. This rapid SOCE acti-
vation in skeletal muscle is most likely due to the lack of Stim1
re-localization from the SR/ER membrane to the plasma membrane
because of its pre-clustering at the junctional SR membrane close
to Orai1 prior to store depletion [87]. Thus Stim1 and Orai1 are
likely (but probably not the only) candidates to mediating SOCE in
mature mammalian skeletal muscles. A link between mutations
in proteins mediating SOCE and myopathies was  unequivocally
provided (i) by the creation of a STIM1 KO mouse model, (ii) the
identification of dominant mutations in STIM1 and ORAI1 in patients
with tubular aggregate myopathy and (iii) the finding that the
absence of Orai1 not only leads to immunological defects but also
to a subtle myopathic phenotype. Homozygous STIM1 KO is almost
always neonatally lethal, the few surviving pups being substan-
tially smaller, with reduced body weight and having weak fatigable
muscles [88]. Histological examination of muscles from KO mice
revealed an increase in the number of centrally located nuclei,
swollen mitochondria and small atrophic fibers; such changes were
accompanied by biochemical modifications of the SR with a signifi-
cant reduction in SERCA1 expression. Myotubes prepared from wild
type, heterozygous and homozygous KO mice responded differ-
ently to depletion of intracellular Ca2+ stores, with myotubes from
the latter almost completely failing to activate Ca2+ influx. Force
measurements on muscles isolated from heterozygous KO mice
confirm that lack of Stim1 causes diminished force development
after tetanic contraction and increased susceptibility to fatigue [88].
It should be mentioned however, that in mouse muscles STIM1
expression peaks at embryonic day 8.5–15.5 and muscles from KO
mice express low levels of MyoD, of MyHC and SERCA. Such a result
is compatible with the hypothesis that this myopathy may  be due
to a defect of skeletal muscle development. In human myotubes,
Stim1-mediated SOCE is required for cell differentiation [89], sup-
porting the idea that the severe phenotype of STIM1 KO mice may
be due to a maturation or developmental block, whereby muscle
cell precursors (myoblasts/myotubes) are incapable of developing
into mature muscle fibers.
Patients with Orai1 deficiency have a complex phenotype char-
acterized by immunodeficiency, ectodermal dysplasia, a defect of
dental enamel calcification and subtle histological features sug-
gestive of a congenital myopathy [90]. Interestingly, a similar
combination of symptoms was  observed in a genetically unre-
solved patient with a histopathological diagnosis of MmD,  reported
before the identification of the Orai1 gene [91]. Cells isolated from
patients carrying mutations causing reduced Orai1expression dis-
play impaired Ca2+ influx while in zebrafish lack of Orai1 leads
to loss of skeletal (and cardiac) muscle integrity and myofibrillar
disruption [92].
Dominant gain of function mutations in STIM1 and ORAI1 are
more frequently encountered in patients with skeletal muscle
involvement. Specifically, they have been identified in several
patients with childhood or adult onset tubular aggregate myopa-normalities in early-onset muscle diseases: Novel concepts and
emcdb.2016.07.017
thy [82–84,93,94] as well as patients with Stormorken syndrome
[95,96] a rare disorder characterized by prolonged bleeding,
thrombocytopenia/thrombocytopathy, asplenia, intellectual dis-
ability, mild hypocalcemia, muscle fatigue and tubular aggregate
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yopathy. Muscle weakness is generally only mild in the adult-
nset cases and some of the patients with an ORAI1 mutation
resented only with exertional cramps [97]. Similarly, the phe-
otype of patients with STIM1 mutations includes cases with
post-exercise) myalgia, fatigability, and calf hypertrophy without
uscle weakness [98]. Interestingly, most STIM1 mutations identi-
ed in patients are located within the NH2 terminal EF hand Ca2+
inding domain of Stim1, leading to a constitutively active molecule
hat oligomerizes and clusters at ER/PM junctions independently of
a2+ store depletion. Theoretically, such Stim1 molecules should
ctivate Ca2+ influx independently of how full the intracellular
a2+ stores are, a hypothesis confirmed in cells carrying STIM1
utations, which exhibit dysregulation of Ca2+ homeostasis char-
cterized by a high resting [Ca2+] and Ca2+ entry independent of
tore depletion [84,93,94,96].
In summary, recent experimental evidence unambiguously sup-
orts a role of SOCE in normal muscle development. Furthermore,
ominant mutations in two players of SOCE lead to a myopathy
haracterized by the accumulation of tubular aggregates deriving
rom the SR. Nevertheless many questions remain unanswered, in
articular the mechanism(s) linking STIM1 and ORAI1 mutations
o accumulation of protein aggregates, how constitutively active
a2+ influx is not compensated by increased activity of Ca2+ pumps
nd extrusion mechanisms and whether alteration of Ca2+ influx
eads to a chronic activation of the Ca2+ dependent phosphatase
alcineurin leading to nuclear localization of NFAT.
.2. Brody’s disease
Brody’s disease is a rare inherited myopathy due to dimin-
shed SERCA1 activity caused by mutations in its encoding gene
TP2A1 [99]. Since a number of patients do not have causative
TP2A1 mutations however, it is now apparent that there is genetic
eterogeneity in Brody’s disease [100,101]. Consequently it has
een proposed to distinguish patients with ATP2A1 mutations
“Brody disease”) from patients with reduced SERCA1 activity with-
ut ATP2A1 mutations (“Brody syndrome”) [102,103]. Reduced
ERCA1 activity results in delayed muscle relaxation due to the
rolonged increase of the myoplasmic [Ca2+] following muscle con-
raction [104]. Two types of SERCA1 are expressed in muscles:
ERCA1 predominantly expressed in type 2 fast-twitch skeletal
uscle and SERCA2 predominantly expressed in type 1 slow-twitch
nd cardiac muscles. Brody’s disease is due to modifications of
ERCA1 only, and accordingly, no cardiac complications have been
eported. Since SERCA1 is only present in fast-twitch muscle fibers,
mpaired relaxation specifically occurs after phasic exercises (alter-
ate contraction and relaxation). In contrast, tonic activity (such as
aintaining posture) requires slow-twitch motor-unit activation,
nd remains unaffected as it predominantly recruits type 1 fibers.
Functional studies on muscle samples from humans with
rody’s disease have demonstrated that some patients exhibit
educed levels of SERCA1 protein content [105,106], while in other
ases the levels of SERCA1 protein are unaltered, but there is a sig-
ificant reduction (up to 80%) in the Ca2+ pumping activity both
n homogenates of muscle samples and in myotubes explanted
rom patients [99,106,107]. Chianina cattle pseudomyotonia, a dis-
ase similar to Brody’s disease affecting cattle, is caused by the
omozygous ATP2A1 p.R164H mutation [108]. The mutation leads
o protein instability and therefore reduced SERCA1 expression.
harmacological inhibition of the ubiquitin/proteasomal system
escues the mutated SERCA1 protein as well as its enzymatic
ctivity [109]. Such results suggest potential pharmacological treat-Please cite this article in press as: S. Treves, et al., Ca2+ handling ab
perspectives, Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.s
ents for patients with Brody’s disease due to mutations leading
o decreased protein stability.
Analysis of the behavior of zebrafish with a naturally occurring
utation in accdta5 (the zebrafish homologue of ATP2A1) provides PRESS
mental Biology xxx (2016) xxx–xxx 7
a useful and sensitive model of Brody’s disease [110]. Accordion
(acc) mutants fail to coil their tails normally after a touch-evoked
stimulus. In contrast, its trunk muscles contract simultaneously to
shorten the trunk resulting in a pronounced dorsal bend, which
might be considered the correlate of a cramp. Subsequent muscle
relaxation is significantly slower in acc than in wild type zebrafish
larvae, corresponding to delayed relaxation in patients. Therefore
the acc zebrafish mutant is considered a valuable model for the
genetic and phenotypic evaluation of Brody’s disease and related
disorders [110].
4. ECC defects in congenital myopathies due to mutations
in genes not directly involved in Ca2+ homeostasis
4.1. SEPN1 related myopathy
Selenoproteins are a group of proteins mediating diverse cel-
lular functions including the maintenance of the cellular redox
status and scavenging reactive oxygen species. As their name indi-
cates, members of this family of proteins contain the unusual
amino acid selenocysteine. Recessive mutations in SEPN1,  the
gene encoding Selenoprotein N (SelN), are commonly associated
with a subgroup of MmD,  CFTD, a congenital form of desmin-
related myopathy and/or Rigid Spine Muscular dystrophy (RSMD1),
early-onset myopathies with a varying but usually severe axial
involvement with scoliosis and respiratory failure. In contrast to
RYR1-related MmD,  extraocular involvement is not a typical fea-
ture. To date more than 40 SEPN1 mutations have been identified,
many of them predicted to result in a truncated protein or in dimin-
ished levels of SelN expression [111–113]. SelN is expressed in
the endoplasmic reticulum of all cells, particularly in fetal tissue
[114], making the mechanistic link between the pathophysiology of
SEPN1 mutations and neuromuscular disorders difficult to unravel.
A first indication connecting SEPN1 mutations to alterations of Ca2+
homeostasis was provided by Arbogast et al. [115] who  demon-
strated increased stress due to increased reactive oxygen and
nitrogen species in myotubes from patients with SEPN1-related
myopathies. More importantly, Ca2+ homeostasis was severely
impaired as indicated by: (i) a 30% increase in the resting cytoso-
lic [Ca2+], (ii) a 50% reduction in the caffeine-induced peak Ca2+
response and (iii) a significant depletion of the SR intracellular
Ca2+ stores. Such an effect was putatively attributed to a RyR1
dysfunction due to secondary modification by free radicals. These
findings are supported by a study by Jurynec et al., who injected
zebrafish eggs with morpholino oligonucleotides targeted to the
exon intron junction of the SEPN1 zebrafish homologue [116]. The
resulting Sepn1 morphant fish display reduced swimming activity,
sarcomeric disorganization and importantly, decreased ryanodine
binding capacity and a diminished responsiveness of RyR1 to the
environmental redox potential, indicating that loss of SelN leads
to a deficit of RyR1 regulation [117]. In order to understand in
greater detail the role of SelN in muscle physiology, a mouse SEPN1
KO model was created (Sepn1−/−) [118]. Surprisingly, under nor-
mal  housing conditions such mice displayed no overt phenotype,
showed no alteration of muscle function, their muscles exhibited
normal ultrastructural organization and there were no changes
in the expression levels of RyR1 and Cav1.1 [119], though they
did display a pronounced reduction of the satellite cell population
[118]. Interestingly, following chronic challenging physical exer-
cise, Sepn1−/− mice showed an obvious phenotype characterized
by muscle rigidity and kyphosis indicating that in mice muscle usenormalities in early-onset muscle diseases: Novel concepts and
emcdb.2016.07.017
and/or environmental stressful conditions are necessary for the
myopathy to develop [119]. In a recent study Marino et al. showed
that the redox activity of SelN protects the ER from peroxides gen-
erated by the ER thiol oxidase protein ERO1. Furthermore, they
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dentified SERCA2 as a redox target of SelN providing evidence of
ts role in regulating ER/SR Ca2+ levels [120].
Clearly much remains to be investigated concerning the patho-
hysiological mechanism(s) underlying SEPN1-related myopathies
nd in particular more mechanistic insight into its effects on Ca2+
omeostasis need to be provided. Studies aimed at investigating
hether the absence of SelN leads to alterations of RyR1 function
ue to changes of its redox status, or secondary posttranslational
odifications are particularly important as they may  reveal mech-
nisms potentially amenable to pharmacological treatment.
.2. MTM1,  BIN1 and DNM2 related disorders
Mutations in MTM1,  the gene encoding the lipid phosphatase
yotubularin 1, are the underlying cause of X-linked myotubu-
ar myopathy (XLMTM), a severe form of CNM characterized by
eneralized muscle weakness, with severe axial, respiratory and
ulbar muscle involvement [121]. Typically symptoms are already
vident at birth and affected males usually die within the first
ear of life without respiratory support. Myotubularin 1 specifi-
ally dephosphorylates phosphatidylinositol-3-phosphate (PI(3)P)
nd phosphatidinylinositol-3,5-bisphosphate (PI(3,5)P2) to pro-
uce PI and PI(5)P respectively [122]. In humans 14 genes encoding
or different myotubularin isoforms have been identified and
ost members of this family play important roles in membrane
rafficking, movement of intracellular vesicles, autophagy and
hagocytosis. Though myotubularin 1 is ubiquitously expressed,
utations in the MTM1  gene result in a selective skeletal muscle
henotype. Studies by Dowling et al. [123] on myotubularin knock
own morphant zebrafish suggest that the specific muscle involve-
ent is due to the lack of expression in muscle of myotubularin
elated proteins (MTMRs). Such proteins compensate for the lack of
yotubularin’s enzymatic activity in other tissues. Although a wide
ange of pathogenic mechanisms have been suggested in associa-
ion with myotubularin 1 deficiency, in the present review we  will
nly focus on mechanisms relevant to Ca2+ homeostasis and ECC.
Two experimental animal models have greatly advanced our
nderstanding of how the absence of myotubularin 1 affects mus-
le function: the Mtm1 KO mouse [124] and the mtm morpholino
nock down zebrafish [123]. In both animal models the most obvi-
us pathological changes occurring in muscle are the presence of
entrally located nuclei with an abnormal appearance, fiber type 1
ypotrophy, abnormal T-tubules and atypical distribution of triads.
uscles from morphant zebrafish show reduced ECC with severely
mpaired muscle contraction evoked by stimuli above 10 Hz [123].
nterestingly, tibialis anterior muscles from asymptomatic Mtm1
O mice at three weeks of age show no changes in expression of pro-
eins involved in Ca2+ homeostasis. However, the tibialis anterior
uscles from Mtm1  KO mice at five weeks of age show a significant
ecrease in the protein content of RyR1 and Cav1.1. Concomitantly
here is a significant increase in the content of the ß1 subunit of
he DHPR [124]. The latter protein is necessary for proper target-
ng of the 1.1 subunit onto T-tubules [125]. Detailed studies on
ntracellular Ca2+ homeostasis showed no difference in the resting
Ca2+], nor in the size if the intracellular Ca2+ stores, however the
eak [Ca2+] evoked by depolarizing pulses was strongly reduced.
hese results support the hypothesis that MTM1  mutations lead
o changes in muscle function by affecting the expression of the
wo main Ca2+ channels involved in ECC, but shed no light on the
echanisms linking myotubularin to the observed changes.
An interesting hypothesis supported by experimental evidence
s that the lipid composition of the membranes in which the DHPRPlease cite this article in press as: S. Treves, et al., Ca2+ handling ab
perspectives, Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.s
nd RyR1 are embedded is important for their function. Indeed,
y confocal immunohistochemistry Dowling et al. showed that
yotubularin localizes to T-tubules and its distribution overlaps
ith that of the DHPR [123]. Along the same lines, in an elegant PRESS
mental Biology xxx (2016) xxx–xxx
report Berthier et al. [126] recently demonstrated that PI(4,5)P2,
another member of the PI family, is not only a constituent of T-
tubules, but that its depletion represses electrically evoked Ca2+
release. These results suggest that this lipid may  either interact
with the RyR1 or affect the activity of the voltage sensor. Although
PI(4,5)P2 is not a substrate of myotubularin 1, alterations in phos-
phoinositide metabolism due to the accumulation of some PIPs
may  alter the lipid composition of the membrane compartments
involved in ECC. The absence of myotubularin 1 should theoreti-
cally cause an accumulation of membrane PI(3)P and PI(3,5)P2 and
increased levels of the latter lipids negatively affect muscle func-
tion by decreasing the size of intracellular Ca2+ stores [127]. While
studying the effect of loss of MTMR14, a PI(3,5)P2 lipid phosphatase
expressed in heart and skeletal muscle, Shen et al. [127] showed
that (i) PI(3)P, PI(5)P and PI(3,5)P2 directly bind to the RyR1 pro-
tein; (ii) PI(3,5)P2 activates the RyR1 and (iii) PI(3,5)P2 promotes the
open conformation of the RyR1 leading to Ca2+ induced Ca2+ release
and depletion of Ca2+ from SR stores. While Rodríguez et al. [128]
showed that microinjection of 100 M PI(3,5)P2 and PI(3) P but not
PI(5)P significantly elevates the resting [Ca2+], all three phospho-
lipids decrease the frequency of spontaneous Ca2+ release events
in skinned fibers, providing further evidence that RyR1 function is
sensitive to its phospholipid environment. These results are inter-
esting but not altogether compatible with the findings of Al Qusari
et al. [124], who showed that the skeletal muscles from Mtm1 KO
mice have normal intracellular Ca2+ stores and normal resting Ca2+
levels and only show a severe reduction of electrically evoked Ca2+
transients.
Muscle function has also been extensively studied in a mouse
model knocked in for MTM1 p.R69C (c.205C > T) [129], a muta-
tion associated with a less severe form of myotubular myopathy
[130,131]. The MTM1 p.R69C mutation putatively affects the bind-
ing domain of PI(3)P/PI(3,5)P2 but not its catalytic domain and
should therefore result in a phosphatase binding less substrate
leading to a hypofunctional enzyme. Detailed genetic investiga-
tions provided evidence that exon skipping occurred in the mouse
model since no full length myotubularin 1 protein was  present; fur-
thermore the muscle levels of PI(3)P were similar in Mtm1 KO mice
and mice knocked in for the mutation, making the interpretation of
the less severe phenotype difficult to explain. These observations
suggest that aside, its lipid phosphatase activity, myotubularin 1
may  have other functions and may  directly regulate the activity of
proteins involved in ECC, thereby contributing to the pathogenesis
of myotubular myopathy.
Milder forms of CNM have been associated with domi-
nant and recessive mutations in BIN1 and DNM2, encoding the
functionally related proteins dynamin 2 and amphiphysin 2,
respectively [132–135]. Dominant mutations in DNM2 are associ-
ated with defective tubular membrane structures [134,135] most
likely because they alter the function of amphiphysin 2 [134].
Amphiphysin 2 is ubiquitously expressed but the skeletal mus-
cle isoform contains a PI binding domain and is localized to the
T-tubules where it plays an important role in T- tubule biogene-
sis [136]. Acute down regulation of Bin1 by siRNA in mouse flexor
digitorum brevis muscle fibers recapitulates T-tubule disruption
as seen in the muscles of affected patients [132]. Furthermore,
murine muscles knocked down for Bin1 show profound alterations
in Ca2+ homeostasis, including depletion of intracellular Ca2+ stores,
reduced membrane current in response to depolarizing pulses lead-
ing to a reduced Ca2+ transient and fewer sparks. Not unexpectedly,
these results confirm that changes in the organization of T-tubules
lead to functional changes in ECC. Though patients with BIN1 muta-normalities in early-onset muscle diseases: Novel concepts and
emcdb.2016.07.017
tions are usually less severely affected than patients with MTM1
mutations and may  develop a child or adult onset congenital mus-
cle diseases [133,137], it should be mentioned that the type of
mutation plays an important role in the phenotype of the patient
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nd that, contrary to patients who generally do not have heart dis-
ase, Bin1 KO mice die shortly after birth because of a hypertrophic
entricular cardiomyopathy.
. Conclusions and outlooks
The past decade has seen enormous progress in our knowledge
oncerning the pathophysiological mechanisms underlying con-
enital myopathies; the identification of the genetic causes and the
unctional characterization of mutations in genes involved directly
r indirectly in Ca2+ regulation and ECC have greatly advanced our
nderstanding of these diseases. The challenges for the upcoming
ears will be to improve the muscle function and thus the quality of
ife of affected patients either by specifically targeting the genetic
efect, as is now being attempted in a preclinical model of MTM1,
r by devising pharmacological strategies aimed at targeting alter-
ative signaling pathways or pathological loops that are activated
n the muscles of affected individuals. The increasing availability
f different animal models with targeted mutations will consider-
bly facilitate the development of experimental therapies and the
dentification of biomarkers that could be used to monitor disease
rogression in affected patients.
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